Bionano Genomics (BNGO) to Release Quarterly Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) is anticipated to announce its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $7.5520 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.12. Bionano Genomics had a negative net margin of 109.94% and a negative return on equity of 71.38%. The company had revenue of $6.69 million during the quarter, compared to analyst estimates of $6.57 million.

Bionano Genomics Stock Up 2.8%

Shares of NASDAQ BNGO traded up $0.03 during mid-day trading on Monday, reaching $1.10. The company had a trading volume of 113,420 shares, compared to its average volume of 230,149. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.59 and a current ratio of 1.84. Bionano Genomics has a twelve month low of $1.00 and a twelve month high of $5.50. The stock’s 50 day moving average is $1.16 and its 200-day moving average is $1.21. The stock has a market capitalization of $12.62 million, a PE ratio of -0.25 and a beta of 1.62.

Institutional Investors Weigh In On Bionano Genomics

Several institutional investors and hedge funds have recently bought and sold shares of BNGO. DRW Securities LLC acquired a new stake in shares of Bionano Genomics during the fourth quarter worth $258,000. Geode Capital Management LLC raised its holdings in Bionano Genomics by 148.8% during the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after buying an additional 39,928 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Bionano Genomics in the 4th quarter valued at about $57,000. Jane Street Group LLC bought a new position in shares of Bionano Genomics during the 4th quarter worth approximately $34,000. Finally, Carret Asset Management LLC increased its stake in Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after buying an additional 19,100 shares during the last quarter. Institutional investors own 11.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BNGO shares. Wall Street Zen raised Bionano Genomics to a “hold” rating in a research note on Saturday, June 13th. HC Wainwright decreased their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, April 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Bionano Genomics in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $6.00.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high?resolution genome analysis tools designed to map structural variants and large?scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase?length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.